OMH Osmetech

 

TIDMOMH 
 
RNS Number : 9075U 
Osmetech PLC 
01 July 2009 
 
 
 
 
 
Osmetech plc ("Osmetech") 
Christopher Gleeson Appointed Chairman 
 
Osmetech plc (OMH.L), a fast growing international molecular diagnostics 
company, is pleased to advise that, further to the announcement on June 25, 
2009, Christopher Gleeson has been appointed non-executive Chairman, effective 
July 1, 2009. Jon Faiz Kayyem, the founder of Clinical Micro Sensors, and the 
inventor of the fundamental Osmetech eSensor technology, becomes Vice Chairman 
effective July 1, 2009. 
 
Gleeson, 59, was formerly President, Chief Executive Officer and a Director 
of Ventana Medical Systems, Inc., ("Ventana") the world's leading supplier of 
automated diagnostic systems to the anatomical pathology market, which was 
acquired by Roche in 2008 for $3.4 billion. Following the acquisition of Ventana 
by Roche in February 2008 and until the end of that year, Mr. Gleeson continued 
as CEO of Ventana and a member of the Board of Roche Diagnostics. 
 
Prior to joining Ventana, Gleeson was senior vice-president of Bayer 
Diagnostics and general manager of the U.S. commercial operations for Chiron 
Diagnostics, and prior to that, the founder, owner, and managing director of 
Australian Diagnostics Corporation, a leading diagnostics company in Australia. 
Gleeson attended the Pharmacy and Business Schools at Monash University in 
Australia. 
 
Osmetech recently raised US$8.6 million, including $1 million from Gleeson, 
via a placing to continue the development and obtain regulatory clearance for 
further tests for Osmetech's eSensor XT?8 System. 
 
Commenting on the appointment, Osmetech Vice Chairman, Jon Faiz Kayyem 
stated, "We are delighted to have Chris Gleeson join our Board as Chairman. 
Having been involved in the innovation and early development of the eSensor 
technology, I recognised that the opportunity today in the broad molecular 
diagnostics field for a simple, low cost, multi-plexed DNA analysis platform, 
such as the Osmetech XT-8 system, was significant. To capitalize on 
this opportunity and to help guide us at the Board level, I felt we needed to 
find someone with deep and successful commercial experience in the diagnostics 
industry and thus we sought out Chris Gleeson. Chris's background in the 
diagnostics industry is extensive and his very successful tenure as the 
President and CEO of a NASDAQ listed company will be invaluable as we expedite 
our menu development plan, drive commercial execution in the U.S. and 
International markets and create long term shareholder value." 
 
In joining Osmetech Board Chris Gleeson commented, "I am delighted to be 
joining Osmetech at a time when the molecular diagnostics market is about to 
witness rapid growth, as new genomic information becomes clinically validated by 
healthcare professionals and pharmaceutical companies. This information, which 
can invariably be provided by the XT-8 system, will likely lead to improved 
diagnosis of certain disease states and treatments that are more efficacious, 
better tolerated and more cost effective." 
 
Gleeson further commented, "The XT-8 platform, which incorporates multiplexed 
DNA eSensor technology, is easy for customers to use and is totally scalable as 
the volume of DNA tests in hospitals and laboratories increases in the future. 
In addition the eSensor technology allows for the rapid development of new DNA 
tests and thus an expanded menu consistent with market demands. I am convinced 
that Osmetech has a market leading technology platform for multiplexed DNA tests 
and I am looking forward to working with the Board and management team to 
realize the opportunity and build a world leading molecular diagnostics 
company." 
 
Osmetech plc     +44 (0)207 849 6027 
James White, Chief Executive Officer 
David Sandilands, Chief Financial Officer 
 
Madano Partnership     +44 (0) 207 593 4000 
Matthew Moth, Mark Way 
www.madano.com 
 
Canaccord Adams Limited                           +44 (0) 20 7050 6500 
Robert Finlay 
Henry Fitzgerald-O'Connor 
 
 
About Osmetech plc 
www.osmetech.com 
 
Osmetech plc is an AIM-listed public company on the London Stock Exchange. The 
Company is a fast developing, international diagnostics business with operations 
in Boston and Pasadena in the US, serving the high growth molecular diagnostic 
market targeting hospitals and reference laboratories. 
 
Osmetech has a strong portfolio of over 200 issued and pending patents and 
has launched its first generation eSensor 4800 platform, an 
electrochemistry-based array system, together with an FDA cleared in vitro 
diagnostic test for Cystic Fibrosis carrier detection. 
 
Osmetech's second generation platform, the eSensor XT-8 received FDA 510(k) 
clearance in July 2008 together with our eSensor Warfarin Sensitivity Test. 
These products are now being marketed in the U.S. together with a 2C9 Genotyping 
Test for drug metabolism and a Cystic Fibrosis carrier detection test which are 
both available for research use purposes only. 
 
The eSensor XT-8 System is designed to support a broad menu of tests and 
Osmetech has scheduled for commercial launch a number of further tests 
including: extended warfarin panel with the proprietary 4F2 marker, venous 
thrombosis (Factor II, Factor V Leiden and MTHFR) and the RESPLEX II respiratory 
pathogen assay in-licensed from Qiagen. The System provides accurate results 
while minimizing technician involvement and its features compare favorably to 
those of other molecular detection systems. Its ease of use, readily 
interpretable results, speed and low maintenance are particularly suited to the 
needs of the decentralizing market. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOARBMMTMMAMBTL 
 

Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025